5 Green Days In A Row: 10x Genomics Stock Is Up 20%
Shares of 10x Genomics (TXG) have closed higher in each of the last 5 sessions, a cumulative gain of 19.5%. That added about $1.9 billion to the company’s market value, which now stands at about $11.7 billion. The stock closed at $90.36 on Wednesday, September 30, its highest close of the past year.
How The Streak Stacks Up Against The S&P 500
Returns for TXG and the S&P 500 over the streak and the periods around it, all ending Wednesday, September 30 and including dividends:
| Return Period | TXG | S&P 500 |
|---|---|---|
| 1 Day | 0.4% | -0.2% |
| 5 Days (Current Streak) | 19.5% | -0.7% |
| 1 Month (21 Trading Days) | 44.7% | -0.3% |
| 3 Months (63 Trading Days) | 131.4% | 2.5% |
| Year To Date | 454.0% | 12.7% |
| 1 Year (252 Trading Days) | 696.8% | 16.2% |
A Stock-Specific Run, Or A Market Move?
The market explains little of this: the S&P 500 lost 0.7% over the same 5 sessions, including dividends, against 10x Genomics’ +19.5%. Over the past three months the stock is up 131.4%, a window that includes the streak; over the other 58 sessions of that window it was up 93.6%.
What The Numbers Say About The Rally
On the fundamentals, revenue declined 4.3% over the last twelve months, against a median of 8.1% for S&P 500 Health Care stocks; and its operating margin is -14.9%, versus a median of 18.3%. 10x Genomics does not have positive trailing earnings, so there is no meaningful price-to-earnings multiple to compare. The numbers make the run harder to justify: shrinking revenue and an operating loss. At this price, the stock is asking a lot of the business.
If you are looking for strength with more behind it than a hot tape, our Guidance Momentum screen surfaces the names where management raised its own outlook.
One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy
A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?
The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Follow the story; invest in the strategy.